Zura Bio (NASDAQ:ZURA) Issues Earnings Results

Zura Bio (NASDAQ:ZURA) posted its quarterly earnings data on Tuesday. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.09, Zacks reports. The firm had revenue of $0.00 million during the quarter.

Zura Bio Stock Up 1.1 %

Shares of NASDAQ:ZURA traded up $0.02 on Thursday, reaching $1.35. 21,164 shares of the company’s stock were exchanged, compared to its average volume of 368,721. The business’s 50-day moving average is $1.48 and its two-hundred day moving average is $2.76. Zura Bio has a fifty-two week low of $1.07 and a fifty-two week high of $6.35.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zura Bio stock. Bank of America Corp DE raised its stake in Zura Bio Limited (NASDAQ:ZURA) by 31.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,222 shares of the company’s stock after acquiring an additional 9,966 shares during the period. Bank of America Corp DE owned 0.06% of Zura Bio worth $103,000 as of its most recent SEC filing. Institutional investors and hedge funds own 61.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on ZURA shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Chardan Capital cut their target price on Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday. HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a research report on Tuesday, December 24th. Oppenheimer restated an “outperform” rating and issued a $19.00 price target (down previously from $20.00) on shares of Zura Bio in a research note on Wednesday. Finally, Guggenheim reiterated a “buy” rating and set a $15.00 price objective on shares of Zura Bio in a research note on Wednesday. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $15.00.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.